855 results on '"Pavoni, M."'
Search Results
2. Effectiveness of high-dose esomeprazole or pantoprazole 10-day sequential therapy empirically prescribed in Helicobacter pylori-infected naïve patients: a retrospective study.
- Author
-
Pavoni M, Fiorini G, Zullo A, Saracino IM, Gatta L, Manta R, Imbrogno A, Lazzarotto T, Borghi C, and Vaira D
- Abstract
Background and Aim: Helicobacter pylori infection is one of the most common bacterial infections affecting humans, causing gastroduodenal and extraintestinal diseases. Treatment of the infection remains challenging for the clinicians, and different factors are involved in the failure of the therapeutic approach. The importance of the intensity of acid secretion inhibition remains an unclear issue. The aim of this study is to assess whether 80 mg/day esomeprazole-based 10-day sequential therapy (esomeprazole-ST) achieved different eradication rates when compared to 80 mg/day pantoprazole-based analogous regimen (pantoprazole-ST)., Methods: This was a retrospective observational study where data of consecutive patients referred by their physicians to our unit to perform an upper gastrointestinal endoscopy were analyzed., Results: Overall, 1,327 patients were available for the analysis: 599 and 728 patients received pantoprazole-ST and esomeprazole-ST, respectively. Eradication rate was significantly higher in patients receiving esomeprazole-ST (92.6%, 95% CI: 91-94.5) than pantoprazole-ST (89.3%, 95% CI: 86.7-91.7; difference: 3.3%; 95% CI: 0.2-6.5; P = 0.037). Even after a multivariate analysis, the esomeprazole-ST achieved a significantly higher eradiation (OR: 1.44; 95% CI: 1.1-2.17)., Conclusions: This study showed that esomeprazole-ST achieved significantly higher H. pylori cure rates than pantoprazole-ST. Prospective and well-designed trials are demander to confirm this prelaminar finding., (© 2024 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. T.12.10: BIOPSIES SAMPLING IN HELICOBACTER PYLORI NEGATIVE PATIENTS: IS IT STILLWORTHY?
- Author
-
Fiorini, G., primary, Pavoni, M., additional, D'Errico, A., additional, Tardio, M.L., additional, Saracino, I.M., additional, Zullo, A., additional, Massarenti, G., additional, Arlotti, L., additional, Borghi, C., additional, and Vaira, B., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Diverticulosis, Adenomas, and Cancer in the Colon: A Systematic Review and Meta-Analysis of Endoscopic Studies.
- Author
-
Del Forno A, Zullo A, Marmo C, Marmo R, Manta R, De Francesco V, Fiorini G, Pavoni M, and Vaira D
- Subjects
- Humans, Prevalence, Diverticulosis, Colonic epidemiology, Diverticulosis, Colonic complications, Diverticulosis, Colonic diagnosis, Risk Factors, Adenoma pathology, Adenoma epidemiology, Colonic Neoplasms pathology, Colonic Neoplasms epidemiology, Colonoscopy
- Abstract
Goals: To perform a systematic review and meta-analysis of endoscopic studies to evaluate an association between diverticulosis and neoplastic lesions in the colon., Background: Some epidemiological observations suggest an association between diverticulosis and adenoma/cancer in the colon. However, an increased risk of colon neoplastic lesions in diverticulosis subjects was found to be increased in some studies, but not in others, puzzling data interpretation., Study: From the retrieved studies, prevalence of adenomas, advanced adenomas, cancer or neoplasia (advanced adenoma or cancer) was compared between subjects with or without diverticulosis, and comparisons in subgroups were also performed., Results: Data of 26 studies with a total of 419,623 patients were eventually considered, including 27,092 patients with diverticulosis. Data analysis found a statistically significant association between diverticulosis and adenomas (OR: 1.88; 95% CI: 1.50-2.25), advanced adenomas (OR: 1.49; 95% CI: 1.02-2.16), and neoplasia (OR: 1.50; 95% CI: 1.11-2.02), but not with cancer alone (OR: 1.01; 95% CI: 0.70-1.47). These associations were confirmed in the subgroup analyses, by considering Caucasian and Asian populations, prospective and retrospective studies, screening or symptoms settings, and between good or fair quality studies., Conclusions: A statistically significant association between diverticulosis and adenomas, advanced adenomas and neoplasia, but not with cancer alone was found. However, the strength of association seems to be insufficient to impact on clinical practice., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Mollaret's Meningitis due to Herpes Simplex Virus 2: A Case Report and Review of the Literature.
- Author
-
Gabrielli L, Banchini I, Petrisli E, Piccirilli G, Venturoli S, Pavoni M, Cantiani A, Lanna F, Campoli C, Montironi M, Giannella M, and Lazzarotto T
- Abstract
Mollaret's meningitis is a rare neurological disorder characterized by recurrent episodes of aseptic lymphocytic meningitis, often associated with herpes simplex virus 2 (HSV-2) infection. We report the case of a 39 y.o. Italian woman who experienced four episodes of aseptic lymphocytic meningitis between 2004 and 2023, diagnosed as Mollaret's meningitis. In each episode, the patient presented with fever, severe headache and photophobia. In two episodes cutaneous vesicles in the left gluteal area preceding meningitis symptoms were also reported. A diagnostic evaluation included a physical-chemical analysis and a real-time PCR of the cerebrospinal fluid (CSF). The CSF presented pleocytosis with lymphocytic predominance and a positive HSV-2 load, with a peak of 1234 copies/mL. The patient was treated successfully with acyclovir, and the symptoms resolved without neurological sequelae. This case highlights the importance of comprehensive diagnostic testing and vigilant monitoring to manage Mollaret's syndrome effectively.
- Published
- 2024
- Full Text
- View/download PDF
6. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
- Author
-
Martínez-Domínguez SJ, Nyssen OP, Lanas Á, Alfaro E, Jonaitis L, Mahmudov U, Voynovan I, Gülüstan B, Rodrigo L, Fiorini G, Perez-Aisa Á, Tejedor-Tejada J, Tepes B, Vologzanina L, Mammadov E, Lerang F, Oğlu QFV, Bakulina NV, Abdulkhakov R, Tatiana I, Butler TJ, Sarsenbaeva AS, Bumane R, Lucendo AJ, Romano M, Bujanda L, Abdulkhakov SR, Zaytsev O, Pabón-Carrasco M, Keco-Huerga A, Denkovski M, Huguet JM, Perona M, Núñez Ó, Pavoni M, Fadieienko G, Alekseenko S, Smith SM, Hernández L, Kupcinskas J, Bordin DS, Leja M, Gasbarrini A, Gridnyev O, Cano-Català A, Parra P, Moreira L, Mégraud F, O'Morain C, and Gisbert JP
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Drug Therapy, Combination, Europe, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori drug effects
- Abstract
Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance., Methods: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis., Results: Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001)., Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all indications., Trial Registration: ClinicalTrials.gov identifier: NCT02328131., (© 2024 The Author(s). Helicobacter published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
7. CMV-RNAemia as new marker of active viral replication in transplant recipients.
- Author
-
Piccirilli G, Lanna F, Gabrielli L, Motta V, Franceschiello M, Cantiani A, Pavoni M, Leone M, Borgatti EC, Gibertoni D, Pascale R, Giannella M, Bonifazi F, and Lazzarotto T
- Subjects
- Humans, Biomarkers blood, Male, Middle Aged, Viremia virology, Female, Adult, Cytomegalovirus Infections virology, Cytomegalovirus Infections diagnosis, Transplant Recipients, Cytomegalovirus genetics, RNA, Viral genetics, RNA, Viral blood, Virus Replication
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
8. Cadmium and copper-induced metabolic and proteomic changes in the root tip during early maize growth.
- Author
-
Matayoshi CL, Jiménez Guaman OM, Esteso ML, Pavoni M, Arán M, Pena LB, and Gallego SM
- Subjects
- Cadmium metabolism, Zea mays metabolism, Meristem metabolism, Hydrogen Peroxide metabolism, Proteomics, Plant Roots metabolism, Copper metabolism, Soil Pollutants metabolism
- Abstract
In this study, the metabolic adjustments performed by maize (Zea mays L.) seminal roots exposed to 25 µM Cd
2+ or 25 µM Cu2+ at pre-emergence are compared, focusing on the proteomic changes after metal exposure. Root width was increased, and root length was decreased after 72 h of metal treatment. Both metals induced H2 O2 accumulation and lipid peroxidation in the root tip. These changes were accompanied by increases in lipoxygenase activity and 4-hydroxy-2-nonenal content. NMR spectroscopy revealed that the abundance of 38 water-soluble metabolites was significantly modified by Cd and Cu exposure; this set of metabolites comprised carboxylic acids, amino acids, carbohydrates, and unidentified phenolic compounds. Linoleic acid content significantly decreased in Cu-treated samples. The total amount of proteins detected in maize root apexes was 2,171. Gene ontology enrichment analysis of the differentially accumulated proteins was performed to detect pathways probably affected by metal additions. Both metals altered redox homeostasis, up-regulated oxylipins biosynthetic process, and shifted metabolism towards the oxidative pentose-phosphate in the root apexes. However, the methionine salvage pathway appears as a key metabolic module only under Cd stress. The integrative analysis carried out in this study suggests that most molecular features behind the reprogramming of maize root tips to cope with cadmium and copper toxicity are common, but some are not., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)- Published
- 2024
- Full Text
- View/download PDF
9. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance.
- Author
-
Bujanda L, Nyssen OP, Ramos J, Bordin DS, Tepes B, Perez-Aisa A, Pavoni M, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Phull PS, Buzás GM, Machado JC, Boltin D, Boyanova L, Tonkić A, Marlicz W, Venerito M, Vologzanina L, Fadieienko GD, Fiorini G, Resina E, Muñoz R, Cano-Català A, Puig I, García-Morales N, Hernández L, Moreira L, Megraud F, Morain CO, Montes M, and Gisbert JP
- Subjects
- Adult, Humans, Anti-Bacterial Agents pharmacology, Bismuth pharmacology, Clarithromycin pharmacology, Drug Resistance, Microbial, Drug Therapy, Combination, Levofloxacin pharmacology, Metronidazole pharmacology, Prospective Studies, Tinidazole pharmacology, Helicobacter Infections drug therapy, Helicobacter Infections microbiology, Helicobacter pylori
- Abstract
Introduction: Antibiotic resistance is one of the main factors that determine the efficacy of treatments to eradicate Helicobacter pylori infection. Our aim was to evaluate the effectiveness of first-line and rescue treatments against H. pylori in Europe according to antibiotics resistance., Methods: Prospective, multicenter, international registry on the management of H. pylori (European Registry on H. pylori Management). All infected and culture-diagnosed adult patients registered in the Spanish Association of Gastroenterology-Research Electronic Data Capture from 2013 to 2021 were included., Results: A total of 2,852 naive patients with culture results were analyzed. Resistance to clarithromycin, metronidazole, and quinolones was 22%, 27%, and 18%, respectively. The most effective treatment, regardless of resistance, were the 3-in-1 single capsule with bismuth, metronidazole, and tetracycline (91%) and the quadruple with bismuth, offering optimal cure rates even in the presence of bacterial resistance to clarithromycin or metronidazole. The concomitant regimen with tinidazole achieved an eradication rate of 99% (90/91) vs 84% (90/107) with metronidazole. Triple schedules, sequential, or concomitant regimen with metronidazole did not achieve optimal results. A total of 1,118 non-naive patients were analyzed. Resistance to clarithromycin, metronidazole, and quinolones was 49%, 41%, and 24%, respectively. The 3-in-1 single capsule (87%) and the triple therapy with levofloxacin (85%) were the only ones that provided encouraging results., Discussion: In regions where the antibiotic resistance rate of H. pylori is high, eradication treatment with the 3-in-1 single capsule, the quadruple with bismuth, and concomitant with tinidazole are the best options in naive patients. In non-naive patients, the 3-in-1 single capsule and the triple therapy with levofloxacin provided encouraging results., (Copyright © 2023 by The American College of Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
10. Integrating controlled-source and ambient noise seismic measures for archaeological prospection: the Scrovegni Chapel case
- Author
-
Barone, I, Cassiani, G, Ourabah, A, Boaga, J, Pavoni, M, and Deiana, R
- Subjects
Geophysics ,Geochemistry and Petrology - Abstract
SUMMARY In this paper, we present the results of an analysis of passive seismic noise recorded around the Scrovegni Chapel in Padua (Italy), using a dense 2-D network with nearly 1500 autonomous seismic nodes. Surface wave tomography using the active records allowed the imaging of several structures located at a depth of few metres, while this study focuses on the processing of about 22 hr of continuous passive records. First, the ambient noise is characterized in terms of amplitude, frequency content and azimuthal distribution, in order to ensure the applicability of the interferometric method. Second, a cross-correlation analysis is performed to retrieve virtual source gathers. Third, traveltimes are extracted from virtual source gathers using the same processing sequence applied to active gathers. Fourth, Eikonal tomography is run to retrieve isotropic phase velocity maps and azimuthal anisotropy. We compare and discuss the results obtained from the active and the passive methods, and finally propose a strategy for the integration of passive and active information. The new quasi-3-D shear wave velocity model obtained from the joint active and passive analysis is more accurate at depth, due to the addition of the passive low-frequency information.
- Published
- 2022
- Full Text
- View/download PDF
11. The Auditory Pathway in Congenitally Cytomegalovirus-Infected Human Fetuses.
- Author
-
Gabrielli L, Bonasoni MP, Piccirilli G, Petrisli E, Venturoli S, Cantiani A, Pavoni M, Marsico C, Capretti MG, Simonazzi G, and Lazzarotto T
- Subjects
- Humans, Cytomegalovirus, Auditory Pathways pathology, Fetus pathology, Cytomegalovirus Infections, Hearing Loss, Sensorineural etiology
- Abstract
Congenital cytomegalovirus (CMV) infection is the main cause of non-hereditary sensorineural hearing loss (SNHL). In order to shed light on SNHL pathophysiology, we examined the auditory pathway in CMV-infected fetuses; the temporal lobe, in particular the auditory cortex, and the inner ear. We investigated both inner ears and temporal lobes of 20 human CMV-infected fetuses at 21 weeks of gestation. As a negative group, five fetuses from spontaneous miscarriages without CMV infection were studied. Inner ears and temporal lobes were histologically examined, immunohistochemistry for CMV and CMV-PCR were performed. On the auditory cortex, we evaluated the local microglial reaction to the infection. CMV-positive cells were found in 14/20 brains and the damage was classified as severe, moderate, or mild, according to histological features. Fetuses with severe brain damage had a statistically higher temporal lobe viral load and a higher number of activated microglial cells in the auditory cortex compared to fetuses with mild brain damage ( p : 0.01; p : 0.01). In the inner ears, the marginal cells of the stria vascularis were the most CMV positive. In our study, CMV affected the auditory pathway, suggesting a tropism for this route. In addition, in the auditory cortex, microglial activation may favor further tissue damage contributing to hearing loss.
- Published
- 2024
- Full Text
- View/download PDF
12. Antimicrobial Resistance of Genital Mycoplasma and Ureaplasma : A Multicentre Study Over a 5-Year Period in Italy (2017-2021).
- Author
-
Pavoni M, Principe L, Foschi C, Meroni E, Briozzo E, Lazzarotto T, Ambretti S, and Di Bella S
- Subjects
- Male, Humans, Female, Adult, Ureaplasma, Azithromycin pharmacology, Azithromycin therapeutic use, Ureaplasma urealyticum, Drug Resistance, Bacterial, Microbial Sensitivity Tests, Mycoplasma hominis, Ciprofloxacin pharmacology, Ciprofloxacin therapeutic use, Genitalia, Prevalence, Anti-Bacterial Agents pharmacology, Mycoplasma Infections drug therapy, Mycoplasma Infections epidemiology
- Abstract
Updated data on genital Mollicutes prevalence and antimicrobial susceptibility can help provide guidance for antibiotic stewardship and set up effective strategies for infection control policies. In this multicentre study, we assessed the prevalence and the resistance profile of Mycoplasma hominis (MH) and Ureaplasma species ( U. parvum/U. urealyticum ), analyzing data from 21,210 subjects who provided urogenital samples for Mollicutes detection by culture over a 5-year period (2017-2021) in two high-density urban areas in the North of Italy ( i.e. , Bologna and Lecco). Overall prevalence of Mollicutes infection was 22.3%, with women showing a significantly higher detection rate than men ( p < 0.00001). The prevalence decreased with age (highest prevalence <30 years) and over the years considered. Ureaplasma strains were much more frequently detected (62.3%) compared to MH (8.3%) and to mixed infections (29.4%). Ureaplasma species showed high levels of ciprofloxacin resistance (39.5%), whereas MH strains were nonsusceptible to azithromycin and roxithromycin in about 60% of cases. Over time, a significant decrease of resistance to azithromycin and doxycycline was detected ( p < 0.0001 and 0.0004, respectively), in parallel with an important increase of ciprofloxacin-resistance levels ( p < 0.0001). Overall, our results revealed that minocycline and josamycin can be first-line drugs for Mollicutes empirical treatment.
- Published
- 2024
- Full Text
- View/download PDF
13. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients
- Author
-
Saracino I.M., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., and Vaira D.
- Subjects
h. pylori ,non-naïve patients ,antibiotic resistance ,antibiotic susceptibility test ,rescue therapies ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Helicobacter pylori (H. pylori) eradication fails in a definite amount of patients despite one or more therapeutic attempts. Curing these patients is progressively more difficult, due to development of antibiotic resistance. Current guidelines suggest testing antibiotic susceptibility in H. pylori isolates following two therapeutic attempts. Aim: to evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy. Methods: consecutive patients, referred to perform upper gastrointestinal endoscopy (UGIE) to our Unit from January 2009 to January 2019 following at least one therapeutic attempt were considered. Bacterial resistance towards clarithromycin, metronidazole and levofloxacin was tested. Patients received either a susceptibility-guided therapy or Pylera®. Results: a total of 1223 patients were H. pylori positive, and antibiotic susceptibility was available for 1037. The rate of antibiotic resistance and MIC values significantly increased paralleling the number of previous therapeutic attempts. Eradication rates of antibiogram-tailored therapies remained stable, except for the sequential therapy if used as a third line. As a rescue treatment, the Pylera® therapy achieved cure rates comparable to those of the other culture-guided therapies. Conclusions: A significant increase in the secondary resistance towards the three tested antibiotics was observed, both as rate and MIC values, in correlation with the number of therapy failures. These findings should be considered when administering an empirical second-line therapy. Pylera® therapy eradication rates are comparable to culture-tailored therapies.
- Published
- 2020
- Full Text
- View/download PDF
14. First-line therapies for H. pylori infection in Italy: a pooled-data analysis
- Author
-
De Francesco, V, primary, Zullo, A, additional, Manta, R, additional, Pavoni, M, additional, Saracino, IM, additional, Fiorini, G, additional, Giostra, F, additional, Monti, G, additional, and Vaira, D, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19
- Author
-
Chiereghin A., Zagari R. M., Galli S., Moroni A., Gabrielli L., Venturoli S., Bon I., Rossini G., Saracino I. M., Pavoni M., Lafratta S., Deni A., Felici S., Borghi M., Guerra L., Raumer L., Lodi V., Viale P., Attard L., Lazzarotto T., Borgatti E. C., Leone M., Mancini R., Petrisli E., Turello G., Gaibani P., Vocale C., Roncarati G., Magnani S., Fioro M. A., Fava M., Marzaduri A., Di Felice G., Caveduri F., Chiereghin A., Zagari R.M., Galli S., Moroni A., Gabrielli L., Venturoli S., Bon I., Rossini G., Saracino I.M., Pavoni M., Lafratta S., Deni A., Felici S., Borghi M., Guerra L., Raumer L., Lodi V., Viale P., Attard L., Lazzarotto T., Borgatti E.C., Leone M., Mancini R., Petrisli E., Turello G., Gaibani P., Vocale C., Roncarati G., Magnani S., Fioro M.A., Fava M., Marzaduri A., Di Felice G., and Caveduri F.
- Subjects
Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Antibodies, Viral ,COVID-19 Serological Testing ,law.invention ,Serology ,03 medical and health sciences ,0302 clinical medicine ,ECLIA and ELISA ,law ,Humans ,Medicine ,030212 general & internal medicine ,Reference standards ,SARS-CoV-2 RT-PCR ,Original Research ,Chemiluminescence ,0303 health sciences ,biology ,Plasma samples ,SARS-CoV-2 ,030306 microbiology ,business.industry ,lcsh:Public aspects of medicine ,SARS-CoV-2 infection ,Public Health, Environmental and Occupational Health ,COVID-19 ,lcsh:RA1-1270 ,LFIA ,SARS-CoV-2-specific antibodies ,Immunoglobulin M ,ROC Curve ,Fully automated ,SARS-CoV-2-specific antibodie ,sensitivity and specificity ,Immunoglobulin G ,Immunology ,biology.protein ,Public Health ,Antibody ,CLIA ,business - Abstract
Introduction: Few data on the diagnostic performance of serological tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently available. We evaluated sensitivity and specificity of five different widely used commercial serological assays for the detection of SARS-CoV-2–specific IgG, IgM, and IgA antibodies using reverse transcriptase-PCR assay in nasopharyngeal swab as reference standard test.Methods: A total of 337 plasma samples collected in the period April–June 2020 from SARS-CoV-2 RT-PCR positive (n = 207) and negative (n = 130) subjects were investigated by one point-of-care lateral flow immunochromatographic assay (LFIA IgG and IgM, Technogenetics) and four fully automated assays: two chemiluminescence immunoassays (CLIA-iFlash IgG and IgM, Shenzhen YHLO Biotech and CLIA-LIAISON® XL IgG, DiaSorin), one electrochemiluminescence immunoassay (ECLIA-Elecsys® total predominant IgG, Roche), and one enzyme-linked immunosorbent assay (ELISA IgA, Euroimmune).Results: The overall sensitivity of all IgG serological assays was >80% and the specificity was >97%. The sensitivity of IgG assays was lower within 2 weeks from the onset of symptoms ranging from 70.8 to 80%. The LFIA and CLIA-iFlash IgM showed an overall low sensitivity of 47.6 and 54.6%, while the specificity was 98.5 and 96.2%, respectively. The ELISA IgA yielded a sensitivity of 84.3% and specificity of 81.7%. However, the ELISA IgA result was indeterminate in 11.7% of cases.Conclusions: IgG serological assays seem to be a reliable tool for the retrospective diagnosis of SARS-CoV-2 infection. IgM assays seem to have a low sensitivity and IgA assay is limited by a substantial rate of indeterminate results.
- Published
- 2021
16. Comparison and Integration of Active and Passive 3D Surface Wave Measures Around the Scrovegni Chapel
- Author
-
Barone, I., primary, Cassiani, G., additional, Ourabah, A., additional, Boaga, J., additional, Pavoni, M., additional, and Deiana, R., additional
- Published
- 2022
- Full Text
- View/download PDF
17. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg).
- Author
-
Nyssen OP, Pratesi P, Spínola MA, Jonaitis L, Pérez-Aísa Á, Vaira D, Saracino IM, Pavoni M, Fiorini G, Tepes B, Bordin DS, Voynovan I, Lanas Á, Martínez-Domínguez SJ, Alfaro E, Bujanda L, Pabón-Carrasco M, Hernández L, Gasbarrini A, Kupcinskas J, Lerang F, Smith SM, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Meštrović A, Marlicz W, Milivojevic V, Simsek H, Kunovsky L, Papp V, Phull PS, Venerito M, Boyanova L, Boltin D, Niv Y, Matysiak-Budnik T, Doulberis M, Dobru D, Lamy V, Capelle LG, Nikolovska Trpchevska E, Moreira L, Cano-Català A, Parra P, Mégraud F, O'Morain C, Ortega GJ, Gisbert JP, and On Behalf Of The Hp-EuReg Investigators
- Abstract
The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection : All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the "most important" variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013-2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin-clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.
- Published
- 2023
- Full Text
- View/download PDF
18. Antibiotic resistance and therapy for H. pylori infection in immigrant patients managed in Italy
- Author
-
Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D., and Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D.
- Subjects
resistance ,therapy ,Helicobacter pylori ,immigrant - Abstract
Background: Helicobacter pylori (H. pylori) infection is the leading cause of both peptic ulcers and gastric tumors, including low-grade MALT-lymphoma and adenocarcinoma. Although it is decreasing in developed countries, H. pylori prevalence remains high in developing areas, mainly due to low socio-economic levels, and the potential consumption of contaminated water. Moreover, a dierent pattern of primary antibiotic resistance is expected in their H. pylori isolates, potentially aecting the ecacy of standard eradication therapies. Indeed, a previous study showed the eradication rate following triple therapy was distinctly lower in dyspeptic H. pylori infected immigrants living in Italy as compared to Italian patients. Aims: to evaluate the resistance pattern in H. pylori isolates from immigrant patients in Italy, and the success rate of first-line therapy in these patients. Materials and Methods: This retrospective study evaluated data of consecutive immigrant patients, diagnosed with H. pylori infection in a single center (Bologna, Italy) between January 2009 and January 2019. Patients underwent first-line therapy with either sequential or Pylera® (Allergan USA, Inc. Madison, NJ, USA) therapy. Results: A total of 609 immigrants were diagnosed with H. pylori infection during the study period, but 264 previously received an eradication therapy. Therefore, the study was focused on 294 out of 345 naïve patients with a successful bacterial culture with antibiogram. Latin America immigrants had the highest overall resistance rate. Levofloxacin resistance rate was significantly higher in Latin Americans and Asians as compared with Europeans. Based on resistance patterns, sequential therapy showed a clear decreasing trend in eradication rates. Conclusions: while antibiotic resistance rates are generally increasing worldwide, Pylera® seems to achieve a good performance as first-line treatment in all naïve foreigner patients, except for Africans.
- Published
- 2020
19. EPV168/#474 Medical care of patients with gynecologic cancer during the covid-19 pandemic: experience of a cancer center in Brazil
- Author
-
Moura, A, primary, Branco, MT, additional, Oliveira, PH, additional, Pavoni, M, additional, Vanzo, A, additional, De Oliveira, V, additional, Barros Junior, A, additional, and Santos, J, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Respiratory Syncytial Virus-Load Kinetics and Clinical Course of Acute Bronchiolitis in Hospitalized Infants: Interim Results and Review of the Literature.
- Author
-
Piccirilli G, Rocca A, Borgatti EC, Gabrielli L, Zama D, Pierantoni L, Leone M, Totaro C, Pavoni M, Lazzarotto T, and Lanari M
- Abstract
Respiratory Syncytial Virus (RSV) bronchiolitis is the leading cause of hospitalization in infants. The role of RSV load in disease severity is still debated. We present the interim results of a prospective monocentric study enrolling previously healthy infants hospitalized for RSV bronchiolitis, collecting nasopharyngeal aspirates every 48 h from admission to discharge, and evaluating RSV load dynamics in relation to clinical outcome measures of bronchiolitis severity, including: need, type and duration of oxygen therapy, length of hospitalization, and the bronchiolitis clinical score calculated at admission. The results showed that the highest viral replication occurs within the first 48 hours after admission, with a significant decrease at subsequent time points ( p < 0.0001). Moreover, higher RSV-RNA values were associated with the need for oxygen therapy ( p = 0.03), particularly high-flow nasal cannula type ( p = 0.04), and longer duration of respiratory support ( p = 0.04). Finally, higher RSV load values were correlated with lower white blood cells, especially lymphocyte counts and C-reactive protein levels ( p = 0.03, p = 0.04, and p = 0.01, respectively), as well as with patients of a younger age ( p = 0.02). These data suggest that RSV may actively contribute to the clinical severity of bronchiolitis, together with other potential non-viral factors.
- Published
- 2023
- Full Text
- View/download PDF
21. OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
22. OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
23. AF.24 CHARACTERISTICS OF EMPIRICAL FIRST- AND SECOND-LINE TREATMENT BETWEEN 2013-2020: ITALIAN DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O’Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
24. OC.08.1 RESCUE THERAPIES FOR H. PYLORI INFECTION IN ITALY
- Author
-
De Francesco, V., primary, Zullo, A., additional, Gatta, L., additional, Manta, R., additional, Pavoni, M., additional, Saracino, I.M., additional, Fiorini, G., additional, and Vaira, B., additional
- Published
- 2021
- Full Text
- View/download PDF
25. OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
- Author
-
Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional
- Published
- 2021
- Full Text
- View/download PDF
26. Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome.
- Author
-
Fiorini G, Saracino IM, Pavoni M, Nipote B, Colucci R, Capone P, Sannino A, Forte F, DE Vergori E, Brancaccio M, Cesareo M, Casella G, Morreale GC, Bonfrate L, Portincasa P, Vincenzi M, Cottone C, Ormando VM, Scalise N, Lawson PF, Burattini O, Montale A, Luzza F, Rossi M, Vanni R, Bozzi R, Vincoli G, Stefani N, Borghi C, and Vaira D
- Subjects
- Humans, Charcoal, Tryptophan, Chamomile, Dietary Supplements, Abdominal Pain drug therapy, Abdominal Pain etiology, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome drug therapy, Glycyrrhiza, Mentha, Gastrointestinal Diseases, Probiotics, Flower Essences, Chronic Pain
- Abstract
Background: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders. IBS is characterized by recurrent chronic abdominal pain and altered bowel habits in the absence of organic damage. Although there are reviews and guidelines for treating IBS, the complexity and diversity of IBS presentation make treatment difficult. Treatment of IBS focuses on relieving symptoms as mild signs and symptoms can often be controlled by managing stress and by making changes in diet and lifestyle. The use of nutraceutical compounds has been advocated as a possible alternative treatment in patients with IBS. COLONIR
® (Omega Pharma Srl, Milan, Italy) may be an alternative or adjuvant treatment in patients with gastrointestinal symptoms. This study aimed to evaluate the effect of this new nutraceutical formulation in inducing symptoms remission and improve gastrointestinal habits., Methods: An initial cohort of 1004 consecutive patients referred to 25 different Units of Internal Medicine a/o Gastroenterology in Italy to perform colonoscopy for intestinal symptoms was asked to participate. Patients were treated for 2 months with two doses of nutraceuticals/day during meals namely COLONIR® . Patients were assessed at baseline and after 2 months to evaluate the frequency and severity of gastrointestinal symptoms in the past seven days with a questionnaire based on ROMA IV criteria., Results: After 2 months, 899 patients completed the follow-up. COLONIR® achieved a statistically significant reduction of severity of symptoms in the study population without any documented side effects., Conclusions: These promising results, here reported, need to be confirmed, valuating the efficacy of COLONIR® in relieving gastrointestinal symptoms in IBS patients in further studies.- Published
- 2023
- Full Text
- View/download PDF
27. Inherited Chromosomally Integrated Human Herpesvirus 6: Laboratory and Clinical Features.
- Author
-
Gabrielli L, Balboni A, Borgatti EC, Virgili G, Petrisli E, Cantiani A, Pavoni M, Baiesi Pillastrini F, Venturoli S, Piccirilli G, and Lazzarotto T
- Abstract
Inherited chromosomally integrated human herpesvirus 6 (iciHHV-6) is a condition in which the complete HHV-6 genome is integrated into the chromosomes of the host germ cell and is vertically transmitted. The aims of this study were to identify iciHHV-6 prevalence in hospitalized patients and clinical features in individuals carrying this integration. HHV-6 PCR on hair follicles was used to confirm iciHHV-6 status when the blood viral load was more than 5 Log
10 copies/mL. From January 2012 to June 2022, HHV-6 DNAemia was investigated in 2019 patients. In particular, 49 had a viral load higher than 6 Log10 copies/mL and HHV-6 DNA in hair follicles was positive. A viral load between 5.0 and 5.9 Log10 copies/mL was observed in 10 patients: 6 infants with acute HHV-6 infection and 4 patients with leukopenia and HHV-6 integration. Therefore, the iciHHV-6 prevalence in our population was 2.6% (53/2019). Adult patients with integration presented hematological (24%), autoimmune (11%), autoimmune neurological (19%), not-autoimmune neurological (22%), and other diseases (19%), whereas 5% had no clinically relevant disease. Although in our study population a high percentage of iciHHV-6 adult hospitalized patients presented a specific pathology, it is still unknown whether the integration is responsible for, or contributes to, the disease development.- Published
- 2023
- Full Text
- View/download PDF
28. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.
- Author
-
Gatta L, Nyssen OP, Fiorini G, Saracino IM, Pavoni M, Romano M, Gravina AG, Granata L, Pellicano R, Gasbarrini A, Di Leo A, Losurdo G, Franceschi F, Nardone G, Rocco A, Dore MP, Farinati F, Ghisa M, Bellini M, Holton J, Puig I, Vaira D, Borghi C, Mégraud F, O'Morain C, and Gisbert JP
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Prospective Studies, Proton Pump Inhibitors therapeutic use, Drug Therapy, Combination, Bismuth therapeutic use, Italy epidemiology, Registries, Helicobacter pylori, Helicobacter Infections diagnosis, Helicobacter Infections drug therapy, Helicobacter Infections epidemiology
- Abstract
Background and Aims: The optimal management of naïve and not naïve Helicobacter pylori patients remains unclear. Therefore, it is essential to evaluate whether the actual clinical practice mirrors the indications suggested by the guidelines. This study aimed to assess the effectiveness and the safety of the empirical first- and second-line treatments prescribed to patients enroled at Italian centres participating in the European Registry on H. pylori Management (Hp-EuReg)., Methods: The Hp-EuReg is an international multicentre prospective non-interventional registry starting in 2013 aiming to evaluate the management of H. pylori infection by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables assessed included demographics, previous eradication attempts, treatment regimen, effectiveness, and tolerance., Results: Overall, 3723 patients from 2013 to February 2021 were included: 2996 and 727 received an empirical first- and second-line treatment, respectively. According to the modified ITT analysis, among the first-line regimens, only the bismuth quadruple therapy with three-in-one-single capsule (BQT-TSC), the concomitant, and the sequential treatment - all lasting 10 days - achieved an eradication rate >90%. Among the second-line regimens, only the 10-day BQT-TSC reported an effectiveness >90%. High-dose PPI twice daily also significantly increased the effectiveness of some therapies. The BQT-TSC was the regimen with the highest incidence of adverse events., Conclusions: Only quadruple therapies lasting at least 10 days achieved over 90% eradication rates among the empirical first- and second-line regimens. It remains unclear whether high-dose PPI twice daily can improve the efficacy of quadruple treatment., (© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
29. Voriconazole Proves Effective in Long-Term Treatment of a Cerebral Cryptococcoma in a Chronic Nephropathic HIV-Negative Patient, after Fluconazole Failure
- Author
-
Sabbatani, S., Manfredi, R., Pavoni, M., Consales, A., and Chiodo, F.
- Published
- 2004
- Full Text
- View/download PDF
30. Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy.
- Author
-
Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, and Vaira D
- Subjects
- Adult, Amoxicillin therapeutic use, Anti-Bacterial Agents therapeutic use, Drug Therapy, Combination, Humans, Helicobacter Infections drug therapy, Helicobacter pylori
- Abstract
Materials and Methods: Consecutive foreigner patients with H. pylori infection following at least one therapy failure were enrolled. All patients underwent upper endoscopy with gastric biopsies used for both histologic examination and culture/susceptibility test. Rescue therapies administered accordingly to susceptibility testing were rifabutin-based therapy, levofloxacin-based therapy, sequential. Pylera was prescribed regardless the resistance pattern., Results: A total of 103 (M/F: 27/76, mean age: 41.9 y, range: 18 to 85) were enrolled. The overall resistance rates toward clarithromycin, metronidazole, and levofloxacin were 76.7%, 66%, and 42.7%, respectively, with triple resistance present in 33.9% of bacterial isolates. Eradication rates were 71.4% on 40 patients for rifabutin-based therapy, 82.8% on 42 cases for levofloxacin-based therapy, 75% on 11 patients treated with sequential therapy, and 100% on 10 cases who received Pylera regimen., Conclusions: To our knowledge, this is the first study assessing H. pylori eradication rates in foreigner patients, who failed at least one therapeutic attempt, managed in Italy. Even by using a culture-based approach, the infection was not cured in a definite number of patients., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. T02.01.18 USE OF PROBIOTICS IN THE HELICOBACTER PYLORI ERADICATION IN ITALY: DATA FROM THE “ITALIAN REGISTRY” ON H. PYLORI TREATMENT
- Author
-
Zagari, R.M., primary, Romiti, A., additional, Saracino, I.M., additional, Ribaldone, D., additional, Panarese, A., additional, Lella, F., additional, Gigliotti, F., additional, Gasbarrini, A., additional, Del Vecchio Blanco, G., additional, Paoluzi, O.A., additional, Romano, M., additional, Annibale, B., additional, Broglia, L., additional, Catanzaro, R., additional, Marfinati Hervoso, C., additional, Luzza, F., additional, Nardone, G., additional, Grande, G., additional, Conigliaro, R., additional, Cannizzaro, R., additional, Fiorini, G., additional, Pavoni, M., additional, Vaira, B., additional, Pellicano, R., additional, Ferrara, M., additional, and Bazzoli, F., additional
- Published
- 2020
- Full Text
- View/download PDF
32. Ultrasound differentiation of two types of de Quervainʼs disease: the role of retinaculum
- Author
-
Volpe, A, Pavoni, M, Marchetta, A, Caramaschi, P, Biasi, D, Zorzi, C, Arcaro, G, and Grassi, W
- Published
- 2010
- Full Text
- View/download PDF
33. Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment
- Author
-
Zagari, R., Romiti, A., Fiorini, G., Saracino, I., Ribaldone, D., Panarese, A., Lella, F., Gigliotti, F., Gasbarrini, A., Paoluzi, O., Del Vecchio Blanco, G., Romano, M., Annibale, B., Broglia, L., Catanzaro, R., Marfinati Hervoso, C., Luzza, F., Nardone, G., Conigliaro, R., Cannizzaro, R., Pavoni, M., Vaira, B., Pellicano, R., Ferrara, M., and Bazzoli, F.
- Published
- 2019
34. Surface wave tomography using dense 3D data around the Scrovegni Chapel in Padua, Italy.
- Author
-
Barone I, Cassiani G, Ourabah A, Boaga J, Pavoni M, and Deiana R
- Abstract
A dense single-node 3D seismic survey has been carried out around the Scrovegni Chapel in Padua (Italy), in order to give new insights about the archaeological setting of the area. The survey made use of nearly 1500 vertical nodes deployed over two rectangular grids. 38 shot positions were fired all around the two receiver patches. The fundamental mode Rayleigh wave signal is here analysed: traveltimes are directly inferred from the signal phases, and phase velocity maps are obtained using Eikonal tomography. Also surface wave amplitudes are used, to produce autospectrum gradient maps. The joint analysis of phase velocity and autospectrum gradient allowed the identification of several buried features, among which possible remains of radial walls of the adjacent Roman amphitheater, structures belonging to a medieval convent, and the root area of an eradicated tree. Finally, depth inversion of 1D dispersion curves allowed the reconstruction of a quasi-3D shear-wave velocity model., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
35. CTG repeats distribution and Alu insertion polymorphism at myotonic dystrophy (DM) gene in Amhara and Oromo populations of Ethiopia
- Author
-
Gennarelli, M., Pavoni, M., Cruciani, F., De Stefano, G., Dallapiccola, B., and Novelli, G.
- Published
- 1999
- Full Text
- View/download PDF
36. First-line therapies for H. pylori infection in Italy: a pooled-data analysis.
- Author
-
De Francesco V, Zullo A, Manta R, Pavoni M, Saracino IM, Fiorini G, Giostra F, Monti G, and Vaira D
- Subjects
- Adult, Amoxicillin therapeutic use, Anti-Bacterial Agents adverse effects, Bismuth therapeutic use, Child, Clarithromycin pharmacology, Clarithromycin therapeutic use, Data Analysis, Drug Therapy, Combination, Humans, Metronidazole therapeutic use, Proton Pump Inhibitors pharmacology, Proton Pump Inhibitors therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori
- Abstract
Background: Curing H. pylori infection remains challenging, and the use of most effective first-line therapy represents a therapeutic cornerstone. To monitor the efficacy of first-line therapies in Italy, we designed a systematic review with pooled- data analysis of data published in the last 15 years., Methods: The search was focused on standard regimens and adult patients. Studies that included modified therapy regimens, pediatric patients, case series with less than 5 patients, and those in language other than English were excluded., Results: A total of 40 studies, with 74 therapeutic arms and 13,539 patients were evaluated. Among the 14-day triple therapies, the combination with proton pump inhibitor (PPI), clarithromycin and amoxicillin achieved the highest (77.9%) success rate, whilst the lowest success rate (62.7%) was observed following the 14-day PPI, clarithromycin and tinidazole regimen. The overall efficacy of triple therapies significantly decreased from 75.7% to 72.1% in the last decade. Sequential (88.3% on 3431 patients), concomitant (88.8% on 376 patients), and the bismuth-based quadruple therapy with three-in-one capsule, containing bismuth subcitrate potassium (140 mg), metronidazole (125 mg), tetracycline (125 mg) (90.4% on 999 patients) achieved similarly high eradication rates, but data on concomitant are still limited. The bismuth-based was associated with the higher (38.7%) incidence of side-effects., Conclusions: Data found that all triple therapies, irrespective of drug combination and therapy duration, should be abandoned in Italy due to their unacceptable low success rates. Monitoring the efficacy of standard first-line therapies in other countries could be clinically useful for both patients and clinicians., Competing Interests: The authors declare that they have no conflict of interest, (© Acta Gastro-Enterologica Belgica.)
- Published
- 2022
- Full Text
- View/download PDF
37. P.01.11 EVALUATION OF THE CURIAN HpSA FLUOROMETRIC ASSAY. A NOVEL, RAPID IMMUNOASSAY FOR THE DETECTION OF HELICOBACTER PYLORI ANTIGENS IN HUMAN STOOL
- Author
-
Saracino, I.M., primary, Pavoni, M., additional, Fiorini, G., additional, Saccomanno, L., additional, and Bibbs, D., additional
- Published
- 2019
- Full Text
- View/download PDF
38. OC.11.3 PCR TEST FOR HELICOBACTER PYLORI DETECTION AND CLARITHROMYCIN RESISTANCE PREDICTION ON FECAL AND BIOPTIC SAMPLES: COMPARISON OF ACCURACIES
- Author
-
Pavoni, M., primary, Turello, G., additional, Saracino, I.M., additional, Fiorini, G., additional, Saccomanno, L., additional, Lazzarotto, T., additional, Vaira, B., additional, and Beckman, E., additional
- Published
- 2019
- Full Text
- View/download PDF
39. Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review.
- Author
-
Francesco V, Zullo A, Manta R, Satriano A, Fiorini G, Pavoni M, Saracino IM, Giostra F, Monti G, and Vaira D
- Abstract
Background: Primary antibiotic resistance in Helicobacter pylori ( H. pylori ) strains is increasing worldwide, affecting therapy success. The use of therapies tailored on susceptibility pre-testing at culture has been proposed, but data are still conflicting., Method: We performed a systematic review to evaluate the role of a culture-based therapeutic approach for H. pylori treatment, taking into account the sensitivity of culture and the success rates achieved with tailored therapies in different therapeutic steps., Results: We analyzed data from 51 studies. Overall, H. pylori strains were isolated in 80.7% of 7889 patients, the success rates being 78.1%, 77.5%, 86.3% and 86.6%, before first-, second-, third-line or more therapies, respectively. In comparative studies, the infection was cured in 89.9% of 2052 patients treated with tailored therapies, and in 77.6% of 2516 patients receiving empiric therapy (P<0.001). However, in the subanalysis, the tailored approach achieved optimal eradication rates (>90%) only when it was applied before first- and second-line therapies, but not before third-line or more attempts (<80%). Moreover, no significant difference emerged between the 2 approaches when data from only the most recent (last 5 years) studies were considered, as well as in those performed in Western populations., Conclusions: The attempt to achieve antibiotic susceptibility testing before treatment failed in 20% of infected patients managed in dedicated laboratories. Culture-tailored therapies administered after 2 or more therapies achieved suboptimal eradication rates. The role of bacterial culture in patients whose therapeutic management failed to eradicate H. pylori probably needs to be corroborated by further data., Competing Interests: Conflict of Interest: None, (Copyright: © Hellenic Society of Gastroenterology.)
- Published
- 2022
- Full Text
- View/download PDF
40. Antifungal Activity of Natural Compounds vs. Candida spp.: A Mixture of Cinnamaldehyde and Eugenol Shows Promising In Vitro Results.
- Author
-
Saracino IM, Foschi C, Pavoni M, Spigarelli R, Valerii MC, and Spisni E
- Abstract
Candida spp. are commensal organisms of the skin, mucous membranes, gastrointestinal tract, blood, and vagina of animals and humans. In recent decades, the incidence of human fungal infections has increased, with Candida spp. (mainly C. albicans ) infections being the most frequent, and the treatment of fungal infections is still a clinical challenge. Colonization of the human gastrointestinal tract by Candida spp. is significant because infections (e.g., candidemia and vulvovaginal candidiasis) frequently arise from commensal microorganisms. The aim of this study was to test in vitro the antifungal activity and the eventual synergistic effect of five pure components of essential oils: cinnamaldehyde, α-pinene, limonene, eucalyptol, and eugenol. These compounds were tested on 18 Candida strains (15 C. albicans , 2 C. glabrata , and 1 C. lusitaniae ) derived from a culture collection of vaginal clinical strains., Methods: Fungistatic activity was evaluated using the disk diffusion method. For fungicidal activity, microdilution and time-kill curve protocols were set up. The checkerboard method was chosen to evaluate a possible synergistic effect of these compounds when mixed., Results: Cinnamaldehyde and eugenol gave the best results, inhibiting all the Candida strains and showing a highly additive effect (FICI 0.625). The cinnamaldehyde inhibition zone (IZ), MIC, and MFC means were 69 mm, 50.05 mg/L, and 109.26 mg/L respectively. Cinnamaldehyde led to the total loss of viable Candida cells within 4 h. Eugenol IZ, MIC, and MFC means were 35.2 mm, 455.42 mg/L, and 690.09 mg/L, respectively. Eugenol led to the total loss of viable fungal cells within 1 h. Treatment with α-pinene inhibited 88.9% of Candida strains, with an IZ mean of 21.2 mm, a MIC mean of 195.41 mg/L, and a MFC mean of 251.27 mg/L; this compound led to the total loss of viable fungal cells only after 24 h. Limonene inhibited only 33.3% of the tested strains and eucalyptol did not produce an inhibition halo, so these compounds were not tested further., Conclusions: These characteristics, together with the well-known safety of cinnamaldehyde and eugenol for human use, make these two natural compounds the perfect candidates for the treatment of candidiasis. This was a pilot study, the purpose of which was to evaluate the best composition of a mixture to be used against intestinal and vulvovaginal candidiasis; in vivo studies are needed to confirm these very encouraging results.
- Published
- 2022
- Full Text
- View/download PDF
41. Feasibility and Effectiveness Assessment of SARS-CoV-2 Antigenic Tests in Mass Screening of a Pediatric Population and Correlation with the Kinetics of Viral Loads.
- Author
-
Lanari M, Biserni GB, Pavoni M, Borgatti EC, Leone M, Corsini I, and Lazzarotto T
- Subjects
- Antigens, Viral analysis, Child, Child, Preschool, Female, Humans, Male, Mass Screening methods, RNA, Viral analysis, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Nucleic Acid Testing methods, COVID-19 Serological Testing methods, Viral Load methods
- Abstract
The gold standard for diagnosis of SARS-CoV-2 infection has been nucleic acid amplification tests (NAAT). However, rapid antigen detection kits (Ag-RDTs), may offer advantages over NAAT in mass screening, generating results in minutes, both as laboratory-based test or point-of-care (POC) use for clinicians, at a lower cost. We assessed two different POC Ag-RDTs in mass screening versus NAAT for SARS-CoV-2 in a cohort of pediatric patients admitted to the Pediatric Emergency Unit of IRCCS-Polyclinic of Sant'Orsola, Bologna (from November 2020 to April 2021). All patients were screened with nasopharyngeal swabs for the detection of SARS-CoV-2-RNA and for antigen tests. Results were obtained from 1146 patients. The COVID-19 Ag FIA kit showed a baseline sensitivity of 53.8% (CI 35.4-71.4%), baseline specificity 99.7% (CI 98.4-100%) and overall accuracy of 80% (95% CI 0.68-0.91); the AFIAS COVID-19 Ag kit, baseline sensitivity of 86.4% (CI 75.0-93.9%), baseline specificity 98.3% (CI 97.1-99.1%) and overall accuracy of 95.3% (95% CI 0.92-0.99). In both tests, some samples showed very low viral load and negative Ag-RDT. This disagreement may reflect the positive inability of Ag-RDTs of detecting antigen in late phase of infection. Among all cases with positive molecular test and negative antigen test, none showed viral loads > 10
6 copies/mL. Finally, we found one false Ag-RDTs negative result (low cycle thresholds; 9 × 105 copies/mL). Our results suggest that both Ag-RDTs showed good performances in detection of high viral load samples, making it a feasible and effective tool for mass screening in actively infected children.- Published
- 2021
- Full Text
- View/download PDF
42. P.10.10 RESCUE THERAPY WITH BISMUTH QUADRUPLE REGIMEN IN PATIENTS WITH HELICOBACTER PYLORI -RESISTANT STRAINS
- Author
-
Fiorini, G., primary, Saracino, I.M., additional, Zullo, A., additional, Gatta, L., additional, Pavoni, M., additional, and Vaira, B., additional
- Published
- 2018
- Full Text
- View/download PDF
43. P.01.21 H. PYLORI RESISTANCE STATUS AND EFFICACY OF SEQUENTIAL THERAPY FOR FIRST-LINE THERAPY: A 6-YEAR EXPERIENCE IN A SINGLE ITALIAN CENTER
- Author
-
Fiorini, G., primary, Zullo, A., additional, Saracino, I.M., additional, Gatta, L., additional, Pavoni, M., additional, and Vaira, B., additional
- Published
- 2018
- Full Text
- View/download PDF
44. P.05.17 EFFICACY OF DIVER-100 IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): PRELIMINARY RESULTS FROM A PROSPECTIVE OBSERVATIONAL COHORT
- Author
-
D'Amico, F., primary, Fiorini, G., additional, Tursi, A., additional, Saracino, I.M., additional, Pavoni, M., additional, Danese, S., additional, and Vaira, D., additional
- Published
- 2018
- Full Text
- View/download PDF
45. P.06.7 BIFIDOBACTERIUM BREVE AND LACTOBACILLUS RHAMNOSUS EFFICACY AS COADJUVANTS IN THE HELICOBACTER PYLORI ERADICATION IN NAÏVE PATIENTS
- Author
-
Fiorini, G., primary, Saracino, I.M., additional, Saccomanno, L., additional, Pavoni, M., additional, and Vaira, B., additional
- Published
- 2018
- Full Text
- View/download PDF
46. OC.14.5 PYLERA AND SEQUENTIAL THERAPY FOR FIRST-LINE H. PYLORI ERADICATION: A CULTURE-BASED STUDY IN REAL CLINICAL PRACTICE
- Author
-
Fiorini, G., primary, Zullo, A., additional, Saracino, I.M., additional, Gatta, L., additional, Pavoni, M., additional, and Vaira, B., additional
- Published
- 2018
- Full Text
- View/download PDF
47. La via Claudia Augusta: recenti indagini archeologiche dell’Università di Verona a Gazzo Veronese (Verona)
- Author
-
Basso, P., Grazioli, V., Pavoni, M., and Zentilini, Elisa
- Subjects
Settore L-ANT/03 - Storia Romana ,Settore L-ANT/09 - Topografia Antica ,Settore L-ANT/07 - Archeologia Classica - Published
- 2016
48. Rescue Therapies for H. pylori Infection in Italy.
- Author
-
De Francesco V, Zullo A, Gatta L, Manta R, Pavoni M, Saracino IM, Fiorini G, and Vaira D
- Abstract
Background/Aims : Curing Helicobacter pylori infection remains challenging for clinicians, as no proposed first-line therapy achieves bacterial eradication in all treated patients so that several patients need two or more consecutive treatments. Bacterial culture with antibiotics susceptibility testing is largely unachievable in Italy, and empiric second-line and rescue therapies are generally used. This study aimed to identify what eradication regimens perform better in Italy, following first-line therapy failure. Methods: We performed a literature search on PubMed for studies on standard therapy regimens used as second-line or rescue treatments performed in adult patients. Studies including modified drug combinations were not considered. Both intention-to-treat and per- protocol analyses were computed for each therapy subgroup. Results: Data from 35 studies with a total of 4830 patients were eventually considered. As a second-line therapy, Pylera
® (90.6%) and a sequential regimen (89.8%) achieved eradication rates significantly higher than other therapies. For third-line therapy, a levofloxacin-based regimen and Pylera® achieved comparable eradication rates (88.2% vs. 84.7%; p = 0.2). Among therapies used as fourth (or more) attempts, Pylera® and a rifabutin-based therapy achieved 77.4% and 66.4% cure rates, respectively ( p = 0.013). A therapy sequence based on the type of first-line therapy used was proposed. Conclusions: Data obtained through our review indicate that standard therapies for H. pylori eradication can be used when following an appropriate sequence, allowing clinicians to improve the cure rate without resorting to bacterial culture.- Published
- 2021
- Full Text
- View/download PDF
49. Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori : A Literature Review.
- Author
-
Saracino IM, Pavoni M, Zullo A, Fiorini G, Lazzarotto T, Borghi C, and Vaira D
- Abstract
Background and aims : Only a few antimicrobials are effective against H. pylori , and antibiotic resistance is an increasing problem for eradication therapies. In 2017, the World Health Organization categorized clarithromycin resistant H. pylori as a "high-priority" bacterium. Standard antimicrobial susceptibility testing can be used to prescribe appropriate therapies but is currently recommended only after the second therapeutic failure. H. pylori is, in fact, a "fastidious" microorganism; culture methods are time-consuming and technically challenging. The advent of molecular biology techniques has enabled the identification of molecular mechanisms underlying the observed phenotypic resistance to antibiotics in H. pylori . The aim of this literature review is to summarize the results of original articles published in the last ten years, regarding the use of Next Generation Sequencing, in particular of the whole genome, to predict the antibiotic resistance in H. pylori. Methods : a literature research was made on PubMed. The research was focused on II and III generation sequencing of the whole H. pylori genome. Results : Next Generation Sequencing enabled the detection of novel, rare and complex resistance mechanisms. The prediction of resistance to clarithromycin, levofloxacin and amoxicillin is accurate; for other antimicrobials, such as metronidazole, rifabutin and tetracycline, potential genetic determinants of the resistant status need further investigation.
- Published
- 2021
- Full Text
- View/download PDF
50. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19.
- Author
-
Chiereghin A, Zagari RM, Galli S, Moroni A, Gabrielli L, Venturoli S, Bon I, Rossini G, Saracino IM, Pavoni M, Lafratta S, Deni A, Felici S, Borghi M, Guerra L, Raumer L, Lodi V, Viale P, Attard L, and Lazzarotto T
- Subjects
- COVID-19 blood, COVID-19 immunology, Humans, Immunoglobulin G blood, Immunoglobulin M blood, ROC Curve, SARS-CoV-2 isolation & purification, Sensitivity and Specificity, Antibodies, Viral blood, COVID-19 diagnosis, COVID-19 Serological Testing, SARS-CoV-2 immunology
- Abstract
Introduction: Few data on the diagnostic performance of serological tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently available. We evaluated sensitivity and specificity of five different widely used commercial serological assays for the detection of SARS-CoV-2-specific IgG, IgM, and IgA antibodies using reverse transcriptase-PCR assay in nasopharyngeal swab as reference standard test. Methods: A total of 337 plasma samples collected in the period April-June 2020 from SARS-CoV-2 RT-PCR positive ( n = 207) and negative ( n = 130) subjects were investigated by one point-of-care lateral flow immunochromatographic assay (LFIA IgG and IgM, Technogenetics) and four fully automated assays: two chemiluminescence immunoassays (CLIA-iFlash IgG and IgM, Shenzhen YHLO Biotech and CLIA-LIAISON
® XL IgG, DiaSorin), one electrochemiluminescence immunoassay (ECLIA-Elecsys® total predominant IgG, Roche), and one enzyme-linked immunosorbent assay (ELISA IgA, Euroimmune). Results: The overall sensitivity of all IgG serological assays was >80% and the specificity was >97%. The sensitivity of IgG assays was lower within 2 weeks from the onset of symptoms ranging from 70.8 to 80%. The LFIA and CLIA-iFlash IgM showed an overall low sensitivity of 47.6 and 54.6%, while the specificity was 98.5 and 96.2%, respectively. The ELISA IgA yielded a sensitivity of 84.3% and specificity of 81.7%. However, the ELISA IgA result was indeterminate in 11.7% of cases. Conclusions: IgG serological assays seem to be a reliable tool for the retrospective diagnosis of SARS-CoV-2 infection. IgM assays seem to have a low sensitivity and IgA assay is limited by a substantial rate of indeterminate results., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Chiereghin, Zagari, Galli, Moroni, Gabrielli, Venturoli, Bon, Rossini, Saracino, Pavoni, Lafratta, Deni, Felici, Borghi, Guerra, Raumer, Lodi, Viale, Attard, Lazzarotto and IRCCS St. Orsola Polyclinic of Bologna COVID-19 Research Team.)- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.